Aethlon Medical, Inc.

Aethlon Medical, Inc. is a medical therapeutic company that focuses on developing the Hemopurifier, a clinical stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The Hemopurifier uses proprietary lectin-based technology to remove life-threatening viruses and harmful exosomes from blood. This technology has potential applications in cancer treatment, where exosomes may promote immune suppression and metastasis, as well as in the treatment of life-threatening infectious diseases.

Founded in 1999 and headquartered in the United States, Aethlon Medical's Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard care therapy. The device also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses not addressed with approved therapies.

The company received a Post-IPO Equity investment on 15 May 2024. The investors involved in this last investment round are not specified. Aethlon Medical operates within the industries of Health Care, Health and Wellness, and Medical Devices.